June 18, 2018 09:30 AM EDT

Johns Hopkins spinout WindMIL grabs $32.5M to fuel its work on a next-gen approach to cell therapy

Amber Tong

New approaches to personalized cancer cell therapies are in no shortage these days. But execs at WindMIL Therapeutics, which has just closed a $32.5 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Johns Hopkins spinout WindMIL grabs $32.5M to fuel its work on a next-gen approach to cell therapy

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Johns Hop­kins spin­out Wind­MIL grabs $32.5M to fu­el its work on a next-gen ap­proach to cell ther­a­py

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Johns Hopkins spinout WindMIL grabs $32.5M to fuel its work on a next-gen approach to cell therapy

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role